Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.81M P/E - EPS this Y 18.70% Ern Qtrly Grth -
Income -171.44M Forward P/E -1.58 EPS next Y 5.30% 50D Avg Chg -20.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.98 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.10 Quick Ratio 4.24 Shares Outstanding 52.67M 52W Low Chg 36.00%
Insider Own 1.92% ROA -49.01% Shares Float 24.10M Beta 1.02
Inst Own 109.19% ROE -92.17% Shares Shorted/Prior 9.99M/9.28M Price 5.77
Gross Margin - Profit Margin - Avg. Volume 218,906 Target Price 9.33
Oper. Margin - Earnings Date Nov 11 Volume 81,047 Change -3.19%
About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Holdings Inc. News
09:35 AM ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11/14/24 ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
11/07/24 ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/04/24 ALX Oncology Announces November Investor Conference Participation
11/01/24 ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
10/10/24 Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc
09/09/24 ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
09/04/24 ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
08/08/24 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/06/24 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
08/01/24 Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
08/01/24 ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
07/31/24 ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
07/31/24 ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
07/09/24 IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
07/09/24 Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
07/08/24 Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
07/05/24 Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
07/04/24 Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
07/03/24 Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
ALXO Chatroom

User Image Golibajje Posted - 2 days ago

$ALXO Well! All makes sense now with that consistent drop from Aug 1. evorpacept doesn’t seem to work and Chief medical officer resigned too! So, the whole pipeline is a sh#t and hedge funds are shorting it consistent to recover their money! Every after hour session, there is a huge sell order like 500k or 700k! Mgmt eyes are on that cash to burn whole next year and moving on!

User Image lucky9150 Posted - 3 days ago

$ALXO , what a piece of junk 😳

User Image Golibajje Posted - 3 days ago

$ALXO Keeping my small position as-is! Not looking good at all! Short shares availability is now 5.1m shares and short % is 57.86%!! Insane! Anticipate a big dump anytime!

User Image Moneywheel Posted - 6 days ago

$ALXO to me, has upside potential. Holding strong. Gap player moving after news released. Potential take-over target at current prices. We need a bit more of negativity here and we might see a reversal pattern with a tp: 3 50$ area.

User Image Golibajje Posted - 6 days ago

$ALXO Institutional selling! Credible folks like Orbimed, Millenium and Venbio, etc.. have sold nearly all of their shares… around 15 million shares! I bought a small chunk today at $1.33 today! But definitely won’t add more for sure. This is going to be a very risky holding with a lot of downward pressure! Clearly see hitting $1

User Image lucky9150 Posted - 6 days ago

$ALXO , horrible 😢 😞 😫

User Image Golibajje Posted - 1 week ago

$ALXO broke the support.. around $1.12 is the next stop if I see it correctly! Hedge funds are holding with an avg of above $6.. so their tax loss selling would push it more down!

User Image lucky9150 Posted - 1 week ago

$ALXO , tax loss selling, take this below $ 1

User Image Golibajje Posted - 1 week ago

$ALXO Support broke.. going below $1.20!! Damn.. so undervalued! Who is selling

User Image lucky9150 Posted - 1 week ago

$ALXO , go where???? 😆

User Image Golibajje Posted - 1 week ago

$ALXO Just penny flipping until month end keeping my core position of 25% and then waiting for data release on Dec 12. So far, I flipped 4 times between 1.45 to $1.60.. made a profit and added more shares to my core position!

User Image lucky9150 Posted - 1 week ago

$ALXO , cannot hold any gains...pathetic POS.

User Image lucky9150 Posted - 1 week ago

$ALXO , On December 12th, they are presenting new data or old stuff again ?

User Image Moe_cash Posted - 1 week ago

$ALXO broke out of this short term downtrend.

User Image Golibajje Posted - 1 week ago

$ALXO Patience pays off here!! Remember they sold shares in Dec 2020 at $76 for raising $208m!! They are trading now in $1.50s with a mkt cap of $81m!! Yesterday’s financials and corporate update was good! We should really ignore short term price action and look for multiple clinical milestones for next year!

User Image justiceforb_85 Posted - 1 week ago

$ALXO frustrating stock. Data for evorpacept is decent and there is a likelihood for future approval.

User Image Golibajje Posted - 1 week ago

$ALXO Mostly traded by the hedge funds right now. Added my first chunk of shares.. keep adding for next few days. Great pipeline, lot of cash and plenty of milestones first half of next year! Keep adding and wait for next year!

User Image Moe_cash Posted - 2 weeks ago

$ALXO sounds good to me.

User Image Golibajje Posted - 2 weeks ago

$ALXO Heavily shorted at the moment.. watching for the bottom to add a big chunk! May be around $1.10. Lot of milestones next year!

User Image gemini112 Posted - 2 weeks ago

$ALXO made some, lost some before. trying my luck again here

User Image Moe_cash Posted - 10/31/24

$ALXO oh oh 👀

User Image jerzypawlik Posted - 10/29/24

$ALXO Just entered the house today with 65k shares, and ready to double that if this goes down. Tremendous opportunities to buy on all time low, and some much cash on hand.

User Image Catracho5 Posted - 10/29/24

$ALXO Found bottom yet?

User Image TraderCrusader37 Posted - 10/29/24

$ALXO why did this stock go down?

User Image ai36r Posted - 10/28/24

$ALXO 💚

User Image Moneywheel Posted - 10/27/24

$ALXO I do believe it can give bulls a surprise. Not selling a single share.

User Image justiceforb_85 Posted - 10/25/24

@Walter100 when do we anticipate data release? Hopefully positive results will increase stock value. I'm still trying to recover from $ALXO data release for evorpacept in gastric cancer.

User Image Jabed206 Posted - 10/25/24

$ALXO has found bottom..lol

User Image theBigDollarski Posted - 10/24/24

@Denaciousrajan $ALXO

User Image Denaciousrajan Posted - 10/24/24

$ALXO predictions today?

Analyst Ratings
UBS Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 13, 24
Cantor Fitzgerald Overweight Aug 12, 24
Stifel Hold Aug 9, 24
Stifel Hold Aug 1, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy Jun 10, 24
Cantor Fitzgerald Overweight May 29, 24
Cantor Fitzgerald Overweight Apr 12, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pinto Shelly VP, Finance and CAO VP, Finance and CAO Dec 29 Sell 11.0699 482 5,336 62,097 01/03/23
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 29 Sell 11.0704 1,617 17,901 270,253 01/03/23
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 11.0701 893 9,886 53,723 01/03/23
Pons Jaume President & CEO President & CEO Dec 29 Sell 11.0701 3,232 35,779 539,746 01/03/23
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 16 Option 3.6 46,474 167,306 271,870 12/20/22
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Feb 07 Option 4.45 15,000 66,750 24,483 02/08/22
Pons Jaume President & CEO President & CEO Feb 03 Option 1.45 24,154 35,023 468,978 02/07/22
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 15 Option 1.45 23,852 34,585 188,396 12/16/21
Lettmann Jason Director Director Dec 13 Sell 27.91 325,377 9,081,272 285,956 12/15/21
LSV Associates, LLC 10% Owner 10% Owner Dec 13 Sell 27.91 48,390 1,350,565 285,956 12/15/21
Lettmann Jason Director Director Dec 08 Sell 32.17 145,637 4,685,142 291,758 12/10/21
LSV Associates, LLC 10% Owner 10% Owner Dec 08 Sell 32.17 145,637 4,685,142 291,758 12/10/21
Pons Jaume President & CEO President & CEO Oct 19 Sell 54.64 16,700 912,488 444,598 10/20/21
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Sep 17 Sell 79.63 12,771 1,016,955 9,331 09/17/21
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Sep 17 Option 4.08 12,771 52,106 20,676 09/17/21
Randolph Sophia Chief Medical Office.. Chief Medical Officer Sep 13 Sell 77.48 7,387 572,345 156,815 09/13/21
Pons Jaume President & CEO President & CEO Aug 20 Sell 63.06 16,700 1,053,102 477,998 08/20/21